Blog
RSS FeedPosted by Michael Wonder on 02 Aug 2017
Rising prices of targeted oral anti-cancer medications and associated financial burden on Medicare beneficiaries
1 August 2017 - The high cost of oncology drugs threatens the affordability of cancer care. ...
Posted by Michael Wonder on 02 Aug 2017
Republicans in Congress bypass Trump to shore up health law
1 August 2017 - Congressional Republicans moved on Tuesday to defuse President Trump’s threat to cut off critical payments to ...
Posted by Michael Wonder on 02 Aug 2017
FDA approves Kalydeco (ivacaftor) for more than 600 people ages 2 and older with cystic fibrosis who have certain residual function mutations
1 August 2017 - Vertex Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) ...
Posted by Michael Wonder on 02 Aug 2017
AiCuris granted fast track designation by U.S. FDA for oral pritelivir for treatment of HSV infections in immunocompromised adults
1 August 2017 - AiCuris today announced that the Company has been granted fast track designation by the U.S. FDA ...
Posted by Michael Wonder on 01 Aug 2017
The Americans who saved health insurance
1 August 2017 - Many Americans look back on the heroic political fights of the past — for suffrage, Social ...
Posted by Michael Wonder on 01 Aug 2017
Express Scripts will exclude more drugs next year, limiting patient choice to save health plans millions
31 July 2017 - Express Scripts, the nation’s largest pharmacy benefits manager, will exclude an additional 64 medicines next year ...
Posted by Michael Wonder on 01 Aug 2017
Sanders to unveil rule requiring drug companies to set fair prices
31 July 2017 - Senator Bernie Sanders will unveil a new rule forcing pharmaceutical companies to set reasonable prices for ...
Posted by Michael Wonder on 01 Aug 2017
FDA approves new targeted treatment for relapsed or refractory acute myeloid leukaemia
1 August 2017 - The U.S. FDA today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory ...
Posted by Michael Wonder on 01 Aug 2017
Bristol-Myers Squibb receives FDA approval for Opdivo (nivolumab) in MSI-H or dMMR metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
1 August 2017 - Approval based on CheckMate -142, in which Opdivo demonstrated an objective response rate of 28% (95% CI: ...
Posted by Michael Wonder on 01 Aug 2017
Indivior RBP-6000 NDA acceptance with priority review designation
31 July 2017 - FDA sets a PDUFA target action date of 30 November 2017. ...
Posted by Michael Wonder on 01 Aug 2017
Kite files the industry's first CAR-T marketing authorisation application in Europe for axicabtagene ciloleucel
31 August 2017 - Submission based on primary analysis of ZUMA-1 in patients with aggressive NHL. ...
Posted by Michael Wonder on 01 Aug 2017
Acalabrutinib granted breakthrough therapy designation by US FDA for the treatment of patients with mantle cell lymphoma
1 August 2017 - AstraZeneca and its haematology research and development centre of excellence, Acerta Pharma, today announced that the US ...
Posted by Michael Wonder on 31 Jul 2017
New system speeds FDA import decisions
31 July 2017 - The data is in. A new automated system for determining whether FDA regulated products can enter the ...
Posted by Michael Wonder on 31 Jul 2017
Imfinzi granted breakthrough therapy designation by US FDA for patients with locally-advanced unresectable non-small-cell lung cancer
31 July 2017 - Fourth breakthrough therapy designation for an AstraZeneca new oncology medicine in three years. ...
Posted by Michael Wonder on 31 Jul 2017
Express Scripts to cover Mylan's EpiPen, exclude rivals
1 August 2017 - Pharmacy benefit manager Express Scripts Holding Co said on Monday it would favour drugmaker Mylan Inc's ...